Latest Safety News

PYC Therapeutics has reported encouraging pre-clinical results for its RNA therapy candidate PYC-002 targeting Phelan-McDermid Syndrome, supporting plans to enter human trials in 2026. The data demonstrate safety, brain distribution, and gene expression restoration in key disease regions.

Core Lithium has significantly increased its Ore Reserves at the Finniss Lithium Project by 42%, secured $54.3 million in fresh capital, and cleared all offtake obligations to advance its restart plans.

Immutep Limited has confirmed 30 mg as the optimal biological dose for its immunotherapy efti, following FDA approval of Project Optimus requirements. This milestone paves the way for the US launch of its pivotal Phase III lung cancer trial.

DPM Metals reports solid third quarter production growth at its Bulgarian mines and steady progress integrating the newly acquired Vareš operation, setting the stage for future expansion.

PYC Therapeutics has reported positive safety outcomes from its Phase 1 trial of PYC-001 for Autosomal Dominant Optic Atrophy, paving the way for a global Phase 1/2 study later this year.

Guzman y Gomez reports robust Q1 FY26 sales growth and network expansion, alongside a significant $100 million share buyback to enhance shareholder value.

Altech Batteries has achieved a major milestone with its Silumina Anodes™, delivering 88.5% capacity retention after 500 cycles and a 40% capacity boost over graphite anodes. This advancement promises longer electric vehicle ranges and lighter battery packs.

Alliance Aviation Services announces founder Scott McMillan will step down as Joint Managing Director at the November AGM, with Stewart Tully set to become sole Managing Director, concluding a year-long succession plan.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

Altech Batteries, in partnership with AMPower, has launched a next-generation 384 V / 15 kWh sodium nickel chloride UPS battery designed specifically for Europe's pipeline infrastructure, promising enhanced safety and reliability in explosive environments.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.